

**Effective for dates of service on or after April 1, 2019:** The following code may be used to identify LUMOXITI® (moxetumomab pasudotox-tdfk)

**NEW**

**C9045, INJECTION, MOXETUMOMAB PASUDOTOX-TDFK, 0.01 MG<sup>1</sup>**

Code	Description	Vial Size	Billing Units
<b>C9045</b>	INJECTION, MOXETUMOMAB PASUDOTOX-TDFK, 0.01 MG	1 mg	1 mg single use vial =100 units

Each provider is responsible for ensuring all coding is accurate and documented in the medical record based on the condition of the patient. The use of this information does not guarantee reimbursement. Health care providers are encouraged to contact payers to confirm code adoption and approved usage prior to submitting claims.

1. Centers for Medicare & Medicaid Services. HCPCS Release & Code Sets. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html>. Accessed March 15, 2019.

**Please see full Prescribing Information, including Boxed Warning.**

AstraZeneca Access 360™ can help with questions you may have about coding and reimbursement. For additional assistance, please contact your Reimbursement Counselor at **1-844-275-2360**, Monday to Friday, 8 AM to 8 PM ET, or visit [www.MyAccess360.com](http://www.MyAccess360.com).

 **1-844-ASK-A360** (1-844-275-2360)

 **1-844-FAX-A360** (1-844-329-2360)

 [Access360@AstraZeneca.com](mailto:Access360@AstraZeneca.com)

 [www.MyAccess360.com](http://www.MyAccess360.com)